Table 1 Relationship of clinical parameters with LGR5 expression in 126 breast carcinoma patients
From: LGR5 overexpression confers poor relapse-free survival in breast cancer patients
| LGR5 IHC | p-value | β-catenin IHC | p-value | |||||
|---|---|---|---|---|---|---|---|---|
| Variables | N | Low (%) | High (%) | N | Low (%) | High (%) | ||
| Total | 126 | 68 (54) | 58 (46) | 119 | 63 (53) | 56 (47) | ||
| Differentiation grade | ||||||||
| I | 3 | 3 (100) | 0 (0) | 0.072 | 2 | 2 (100) | 0 (0) | 0.377 |
| II | 93 | 53 (57) | 40 (43) | 88 | 45 (51) | 43 (49) | ||
| III | 30 | 12 (41) | 18 (59) | 29 | 16 (55) | 13 (45) | ||
| Age group | ||||||||
| < = 35 | 7 | 5 (71) | 2 (29) | 0.775 | 7 | 4 (57) | 3 (43) | 0.419 |
| 36–45 | 28 | 15 (54) | 13 (46) | 28 | 15 (54) | 13 (46) | ||
| 46–55 | 47 | 27 (57) | 20 (43) | 42 | 23 (55) | 19 (45) | ||
| 56–65 | 27 | 13 (48) | 14 (52) | 26 | 10 (38) | 16 (62) | ||
| > 65 | 17 | 8 (47) | 9 (53) | 16 | 11 (69) | 5 (31) | ||
| Tumor size (cm) | ||||||||
| < 2 | 44 | 33 (75) | 11 (25) | 0.002 | 41 | 21 (51) | 20 (49) | 0.910 |
| 2–5 | 70 | 40 (43) | 30 (57) | 66 | 35 (53) | 31 (47) | ||
| > 5 | 12 | 5 (39) | 7 (61) | 12 | 7 (58) | 5 (42) | ||
| LN metastasis | ||||||||
| Negative | 75 | 46 (61) | 29 (39) | 0.044 | 70 | 36 (51) | 34 (49) | 0.693 |
| Positive | 51 | 22 (43) | 29 (57) | 49 | 27 (55) | 22 (45) | ||
| Histopathological feature | ||||||||
| Invasive ductal carcinoma | 121 | 65 (54) | 56 (46) | 0.830 | 114 | 60 (53) | 54 (47) | 0.178 |
| Invasive mucinous carcinoma | 1 | 1 (100) | 0 (0) | 1 | 1 (100) | 0 (0) | ||
| Invasive lobular carcinoma | 2 | 1 (50) | 1 (50) | 2 | 2 (100) | 0 (0) | ||
| Metaplastic carcinoma | 2 | 1 (50) | 1 (50) | 2 | 0 (0) | 2 (100) | ||
| ER status | ||||||||
| Negative | 49 | 22 (45) | 27 (55) | 0.103 | 46 | 22 (48) | 24 (52) | 0.375 |
| Positive | 77 | 46 (60) | 31 (40) | 73 | 41 (56) | 32 (44) | ||
| PR status | ||||||||
| Negative | 63 | 31 (49) | 32 (51) | 0.284 | 59 | 30 (51) | 29 (49) | 0.650 |
| Positive | 63 | 37 (59) | 26 (41) | 60 | 33 (55) | 27 (45) | ||
| HER2 status | ||||||||
| Negative | 59 | 27 (46) | 32 (54) | 0.097 | 55 | 35 (64) | 20 (36) | 0.037 |
| Positive | 66 | 40 (60) | 26 (40) | 63 | 28 (44) | 35 (56) | ||
| Missing | 1 | 1 | ||||||
| Molecular subtype | ||||||||
| Non-TNBC | 109 | 63 (57) | 46 (43) | 0.029 | 102 | 57 (56) | 45 (44) | 0.115 |
| TNBC | 17 | 5 (37) | 12 (63) | 17 | 6 (35) | 11 (65) | ||
